|
1
|
WHO. The global burden of disease 2004
update. World Health Organization; Geneva: (part 2): pp. 12–13.
2004
|
|
2
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Estimating the world cancer burden: Globocan 2000. Int J Cancer.
94:153–156. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
London WT and McGlynn KA: Liver cancer.
Cancer Epidemiology and Prevention. Schottenfeld D and Fraumeni JF
Jr: 3rd edition. Oxford University Press; New York: pp. 763–786.
2006, View Article : Google Scholar
|
|
4
|
Sementchenko VI and Watson DK: Ets target
genes: past, present and future. Oncogene. 19:6533–6548. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Naito S, Shimizu S, Matsuu M, et al: Ets-1
upregulates matrix metalloproteinase-1 expression through
extracellular matrix adhesion in vascular endothelial cells.
Biochem Biophys Res Commun. 291:130–138. 2002. View Article : Google Scholar
|
|
6
|
Kitange G, Tsunoda K, Anda T, et al:
Immunohistochemical expression of Ets-1 transcription factor and
the urokinase-type plasminogen activator is correlated with the
malignant and invasive potential in meningiomas. Cancer.
89:2292–2300. 2000. View Article : Google Scholar
|
|
7
|
Behrens P, Rothe M, Wellmann A, Krischler
J and Wernert N: The Ets-1 transcription factor is up-regulated
together with MMP 1 and MMP 9 in the stroma of pre-invasive breast
cancer. J Pathol. 194:43–50. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Takanami I, Takeuchi K and Karuke M:
Expression of ETS-1 is correlated with urokinase-type plasminogen
activator and poor prognosis in pulmonary adenocarcinoma. Tumour
Biol. 22:205–210. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Behrens P, Rothe M, Florin A, Wellmann A
and Wernert N: Invasive properties of serous human epithelial
ovarian tumors are related to Ets-1, MMP-1 and MMP-9 expression.
Int J Mol Med. 8:149–154. 2001.PubMed/NCBI
|
|
10
|
Nakada M, Yamashita J, Okada Y and Sato H:
Ets-1 positively regulates expression of urokinase-type plasminogen
activator (uPA) and invasiveness of astrocytic tumors. J
Neuropathol Exp Neurol. 58:329–334. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
El-Serag HB and Rudolph KL: Hepatocellular
carcinoma: epidemiology and molecular carcinogenesis.
Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wurmbach E, Chen YB, Khitrov G, et al:
Genome-wide molecular profiles of HCV-induced dysplasia and
hepatocellular carcinoma. Hepatology. 45:938–947. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lee JS and Thorgeirsson SS: Comparative
and integrative functional genomics of HCC. Oncogene. 25:3801–3809.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lemmer ER, Friedman SL and Llovet JM:
Molecular diagnosis of chronic liver disease and hepatocellular
carcinoma: the potential of gene expression profiling. Semin Liver
Dis. 26:373–384. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bartel DP: MicroRNAs: target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ventura A and Jacks T: MicroRNAs and
cancer: short RNAs go a long way. Cell. 136:586–591. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kumar MS, Lu J, Mercer KL, Golub TR and
Jacks T: Impaired microRNA processing enhances cellular
transformation and tumorigenesis. Nat Genet. 39:673–677. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lu J, Getz G, Miska EA, et al: MicroRNA
expression profiles classify human cancers. Nature. 435:834–838.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ozen M, Creighton CJ, Ozdemir M and
Ittmann M: Widespread deregulation of microRNA expression in human
prostate cancer. Oncogene. 27:1788–1793. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Budhu A, Jia HL, Forgues M, et al:
Identification of metastasis-related microRNAs in hepatocellular
carcinoma. Hepatology. 47:897–907. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li LM, Hu ZB, Zhou ZX, et al: Serum
microRNA profiles serve as novel biomarkers for HBV infection and
diagnosis of HBV-positive hepatocarcinoma. Cancer Res.
70:9798–9807. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhou J, Yu L, Gao X, et al: Plasma
microRNA panel to diagnose hepatitis B virus-related hepatocellular
carcinoma. J Clin Oncol. 29:4781–4788. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ladeiro Y, Couchy G, Balabaud C, et al:
MicroRNA profiling in hepatocellular tumors is associated with
clinical features and oncogene/tumor suppressor gene mutations.
Hepatology. 47:1955–1963. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kanda K, Nakayama T, Onizuka S, Tomioka T
and Kanematsu T: Expression of the Ets-1 proto-oncogene is linked
to cell differentiation of human hepatocellular carcinoma.
Hepatogastroenterology. 49:747–751. 2002.PubMed/NCBI
|
|
27
|
Cui J, Fu H, Feng J, Zhu J, Tie Y, Xing R,
Wang C and Zheng X: The construction of miRNA expression library
for human. Progr Biochem Biophys. 34:389–394. 2007.
|
|
28
|
Nakamura T, Nishizawa T, Hagiya M, et al:
Molecular cloning and expression of human hepatocyte growth factor.
Nature. 342:440–443. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Calin GA, Sevignani C, Dumitru CD, et al:
Human microRNA genes are frequently located at fragile sites and
genomic regions involved in cancers. Proc Natl Acad Sci USA.
101:2999–3004. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Span PN, Manders P, Heuvel JJ, et al:
Expression of the transcription factor Ets-1 is an independent
prognostic marker for relapse-free survival in breast cancer.
Oncogene. 21:8506–8509. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Naito S, Shimizu K, Nakashima M, et al:
Overexpression of Ets-1 transcription factor in angiosarcoma of the
skin. Pathol Res Pract. 196:103–109. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Oda N, Abe M and Sato Y: ETS-1 converts
endothelial cells to the angiogenic phenotype by inducing the
expression of matrix metalloproteinases and integrin beta3. J Cell
Physiol. 178:121–132. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sato Y, Abe M, Tanaka K, et al: Signal
transduction and transcriptional regulation of angiogenesis. Adv
Exp Med Biol. 476:109–115. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jiang Y, Xu W, Lu J, He F and Yang X:
Invasiveness of hepatocellular carcinoma cell lines: contribution
of hepatocyte growth factor, c-met, and transcription factor Ets-1.
Biochem Biophys Res Commun. 286:1123–1130. 2001. View Article : Google Scholar
|
|
35
|
Tamagnone L and Comoglio PM: Control of
invasive growth by hepatocyte growth factor (HGF) and related
scatter factors. Cytokine Growth Factor Rev. 8:129–142. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Paumelle R, Tulasne D, Kherrouche Z, et
al: Hepatocyte growth factor/scatter factor activates the
ETS1 transcription factor by a RAS-RAF-MEK-ERK signaling
pathway. Oncogene. 21:2309–2319. 2002.PubMed/NCBI
|
